Biological E Partners with Bavarian Nordic to Boost Chikungunya Vaccine Access in Low-Income Nations

Biological E Limited and Bavarian Nordic pair up to expand the Chikungunya Vaccine reach in low-and middle-income countries. This alliance involves technology transfer for manufacturing, contingent on regulatory approvals, and promises up to 300 new jobs in Hyderabad. The mutually beneficial endeavor targets enhanced prevention against Chikungunya globally.

In a significant move to broaden the reach of lifesaving vaccines, Biological E Limited has joined hands with Bavarian Nordic to ensure wider access to the Chikungunya Vaccine in low-and middle-income countries. This strategic partnership includes a technology transfer deal for the current drug product manufacturing process and may include the drug substance process in the future.

The collaboration isn't just about expanding vaccine supply; it is poised to create up to 300 new jobs at Biological E's Genome Valley facilities in Hyderabad. Following regulatory green lights, commercial manufacturing will commence, bolstering availability for endemic regions.

As Bavarian Nordic celebrates its first U.S. approval for the vaccine and awaits European regulatory decisions, this first collaboration with Biological E epitomizes a commitment to global health. Leaders Mahima Datla and Paul Chaplin emphasize their efforts to furnish vaccines where needed most, leveraging their expertise and infrastructure to combat the public health threat posed by Chikungunya virus globally.